3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
350
Stomach Neoplasms
31
Neoplasm Metastasis
30
Breast Neoplasms, Male
25
Neoplasms
16
Inflammatory Breast Neoplasms
12
Brain Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Esophageal Neoplasms
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Urinary Bladder Neoplasms
5
Rectal Neoplasms
5
Adenocarcinoma
5
Sarcoma
4
Lung Neoplasms
4
HER2-positive Breast Cancer
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Triple Negative Breast Neoplasms
3
Salivary Gland Neoplasms
3
Head and Neck Neoplasms
3
HER2 Positive Breast Cancer
3
Cardiotoxicity
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Hepatocellular
3
Carcinoma, Ductal, Breast
3
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Trastuzumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts